BUVIDAL®

INTRODUCING THE FIRST WEEKLY/MONTHLY LONG-ACTING INDIVIDUALISED TREATMENT FOR OPIOID DEPENDENCE

BUVIDAL®

INTRODUCING THE FIRST WEEKLY/MONTHLY LONG-ACTING
INDIVIDUALISED TREATMENT FOR OPIOID DEPENDENCE

Buvidal is indicated for:

  • Treatment of opioid dependence within a framework of medical, social and psychological treatment.
  • Treatment is intended for use in adults and adolescents aged 16 years or over.

Administration of Buvidal is restricted to healthcare professionals.

Appropriate precautions, such as to conduct patient follow-up visits with clinical monitoring according to the patient’s needs, should be taken when prescribing and dispensing buprenorphine. Take-home use or self-administration of the product by patients is not allowed.

Buvidal can be administered as either a weekly or a monthly injection.

Buvidal is available in the following doses:

For weekly injection:

Pre-filled syringes containing Buvidal 8 mg (0.16ml), 16 mg (0.32ml), 24 mg (0.48ml) and 32 mg (0.64ml) prolonged-release solution for injection.

For monthly injection:

Pre-filled syringes containing Buvidal 64 mg (0.18ml), 96 mg (0.27ml), 128 mg (0.36ml) and 160 mg (0.45ml) prolonged-release solution for injection.

Contact us

Sitemap

Privacy notice

Terms of use

© 2021 Camurus AB. All rights reserved | INT-BUV-2100026 | Date of preparation: June 2021 | Based on the EU SmPC May 2021